title: When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis.
abstract: Patients with psoriasis and psoriatic arthritis respond to anti-TNF therapy, but not all patients maintain effective response, and some do not respond. In this article, we demonstrate the role of a new pathogenetic pathway to some extent TNF-independent in these patients. Anti-IL12-23 is a new and alternate mode of therapy for patients with recalcitrant response to anti-TNF.
authors: Ricardo Prado
authors: RP
authors: Golmia
authors: Ayk Helena Barbosa
authors: AH
authors: Martins
authors: Morton
authors: M
authors: Scheinberg
mesh_terms: D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors*; D053759:Interleukin-23 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12